Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2847
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Clinical Validation of a Prognostic 11-Gene Expression Profiling Score in Prospectively Collected FFPE Tissue of Patients With AJCC V8 Stage II Cutaneous Melanoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Considering Adjuvant Therapy for Stage II Melanoma

Cancer
Cancer ResearchOncology
2019English

784 a New Immune Evasion Mechanism in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma

Cancer Research
Cancer ResearchOncology
2019English

Cell Kinetics: An Independent Prognostic Variable in Stage II Melanoma of the Skin

British Journal of Cancer
Cancer ResearchOncology
1990English

H3K27me3 and EZH2 Expression in Melanoma: Relevance for Melanoma Progression and Response to Immune Checkpoint Blockade

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2020English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

Is There a Role for Immune Checkpoint Blockade in Metastatic Uveal Melanoma?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Use of a Prognostic Gene Expression Profile Test for T1 Cutaneous Melanoma: Will It Help or Harm Patients?

Journal of the American Academy of Dermatology
Dermatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy